To provide the information your oncologist is not telling you or doesn't have the time to!
If you’ve ever picked up a brightly colored candy or a strawberry-flavored treat, chances are you’ve encountered Red Dye No. 3, a synthetic food dye known for its vibrant hue. Despite its eye-catching appeal, Red Dye No. 3 has long been surrounded by controversy due to potential health risks. Recently, the U.S. Food and Drug …
On December 27, 2024, the FDA announced a significant milestone in cancer treatment: the approval of nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection. This new formulation is available for all adult solid tumor indications previously approved for intravenous (IV) nivolumab, including a wide range of cancers such as melanoma, renal cell carcinoma, non-small cell lung cancer, …
On December 20, 2024, the FDA granted accelerated approval for a groundbreaking new treatment approach for patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. The newly approved regimen combines encorafenib (Braftovi) with cetuximab and mFOLFOX6 (a chemotherapy regimen consisting of fluorouracil, leucovorin, and oxaliplatin). This marks a pivotal step forward in the …
As oncologists, we are privileged to walk alongside patients and their families during some of the most challenging times in their lives. This responsibility becomes even more pronounced when we step into a role as a covering physician, whether temporarily filling in for a partner or taking on a temporary locum tenens assignments as I …
Multiple myeloma, a complex and challenging hematologic malignancy, has seen remarkable advances in its treatment landscape. Standard care for transplant-eligible patients often involves quad therapy, blending immunomodulatory agents, proteasome inhibitors, anti-CD38 monoclonal antibodies, and corticosteroids. For frail or comorbid patients, triple therapy remains the mainstay. Hospitalized patients frequently benefit from CyBORD (cyclophosphamide, bortezomib, dexamethasone), and …
Cancer cachexia is a debilitating condition that affects a significant portion of cancer patients, characterized by involuntary weight loss, muscle wasting, and metabolic dysfunction. Beyond its physical toll, cachexia diminishes quality of life and complicates cancer treatment, making it a critical issue in oncology. Despite its prevalence, effective treatments have been limited—until now. Recent advancements, …
Stage IV melanoma used to be synonymous with a terminal diagnosis. For years, oncologists faced the grim reality of limited options and poor survival rates for their patients. However, the landscape has changed dramatically over the past decade. Breakthroughs in immunotherapy and clinical research have rewritten the narrative, offering hope to patients and their families. …
As the holiday season wraps up and 2024 comes to a close, I find myself reflecting on a year that has been both transformative and rejuvenating. This year has been different from any I’ve experienced before—a year of intentional living, personal growth, and deep gratitude. For the past 13 years, I was rooted in a …
Medical malpractice in oncology is a topic that often stirs emotions on all sides—patients, families, and physicians. For patients and caregivers, it may represent a loss of trust and unmet expectations. For providers, it can be a deeply personal challenge that touches the very heart of their commitment to care. In oncology, where time, precision, …
The management of chronic lymphocytic leukemia (CLL), one of the most common types of leukemia, has advanced significantly over the past decade. New targeted therapies have reshaped treatment paradigms, providing effective, less toxic options compared to traditional chemoimmunotherapy. At the 2024 ASH Annual Meeting, data from the phase 3 AMPLIFY trial introduced another potential breakthrough …